Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Medical Center, Washington, DC.
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Medical Center, Washington, DC.
Transplant Cell Ther. 2022 Oct;28(10):650-656. doi: 10.1016/j.jtct.2022.06.025. Epub 2022 Jul 3.
The advent of chimeric antigen receptor (CAR) engineering has led to the development of powerful cellular therapies for cancer. CAR T cell-based treatments have had notable clinical success, but logistical issues and associated toxicities are recognized limitations. There is emerging interest in using other immune effector cell types for CAR therapy. Natural killer (NK) cells are part of the innate immune system, and these lymphocytes play major roles in immunosurveillance and antitumor immune responses. Incorporating CARs into NK cells provides the opportunity to harness and enhance their innate cytotoxic potential toward malignancies. In this review, we discuss the production of CAR-engineered NK cells, highlight data on their preclinical and clinical efficacy, and examine the obstacles and strategies to overcome them.
嵌合抗原受体 (CAR) 工程的出现推动了癌症的细胞治疗发展。基于 CAR T 细胞的治疗方法取得了显著的临床成功，但物流问题和相关毒性是公认的局限性。人们对使用其他免疫效应细胞类型进行 CAR 治疗越来越感兴趣。自然杀伤 (NK) 细胞是先天免疫系统的一部分，这些淋巴细胞在免疫监视和抗肿瘤免疫反应中发挥重要作用。将 CAR 整合到 NK 细胞中提供了利用和增强其对恶性肿瘤固有细胞毒性潜力的机会。在这篇综述中，我们讨论了 CAR 工程 NK 细胞的生产，强调了它们的临床前和临床疗效数据，并研究了克服这些障碍的策略。
